Granulated mesalamine

DRUG2 trials

Sponsors

Bausch Health Americas, Inc.

Conditions

Ulcerative Colitis

Phase 3

Mesalamine Pellet Formulation to Maintain Remission of Mild to Moderate Ulcerative Colitis

CompletedNCT00744016

Bausch Health Americas, Inc.Ulcerative Colitis

Start: 2004-12-31End: 2007-10-31Updated: 2019-11-27

Mesalamine Pellet to Maintain Remission of Mild to Moderate Ulcerative Colitis

CompletedNCT00767728

Bausch Health Americas, Inc.Ulcerative Colitis

Start: 2004-12-31End: 2007-10-31Updated: 2019-11-27

Related Papers

Once-daily mesalamine granules for maintaining remission of ulcerative colitis: pooled analysis of efficacy, safety, and prognostic factors

Postgraduate Medicine2016-02-1012 citations

Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission.

2015-11-125 citations

Mesalazine granules 1.5 g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: a pooled analysis from two randomised controlled trials.

2012-05-238 citations